$0.46
0.00%
Nasdaq, Aug 30, 01:59 am CET
ISIN
US72941H4002
Symbol
PSTV

Plus Therapeutics Inc Stock price

$0.46
-0.07 13.60% 1M
-0.27 37.10% 6M
-0.69 60.35% YTD
-0.96 67.89% 1Y
-14.54 96.96% 3Y
-36.29 98.76% 5Y
-40,735.79 100.00% 10Y
-517,499.54 100.00% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.03 6.90%
ISIN
US72941H4002
Symbol
PSTV
Industry

Key metrics

Basic
Market capitalization
$45.3m
Enterprise Value
$38.4m
Net debt
positive
Cash
$6.9m
Shares outstanding
92.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.5 | 7.5
EV/Sales
7.2 | 6.4
EV/FCF
negative
P/B
14.9
Financial Health
Equity Ratio
-134.9%
Return on Equity
145.0%
ROCE
-421.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$5.3m | $6.0m
EBITDA
$-12.2m | $-12.2m
EBIT
$-12.8m | $-17.0m
Net Income
$-19.0m | $-61.7m
Free Cash Flow
$-16.9m
Growth (TTM | estimate)
Revenue
-3.5% | 3.0%
EBITDA
9.8% | 12.4%
EBIT
9.4% | -15.6%
Net Income
-43.8% | -375.7%
Free Cash Flow
-58.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-228.6% | -204.1%
EBIT
-240.2%
Net
-357.9% | -1,029.7%
Free Cash Flow
-317.8%
More
EPS
$-0.1
FCF per Share
$-0.2
Short interest
3.2%
Employees
21
Rev per Employee
$280.0k
Show more

Is Plus Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Plus Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Plus Therapeutics Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Plus Therapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Plus Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5.32 5.32
3% 3%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
14% 14%
189%
- Research and Development Expense 8.05 8.05
26% 26%
151%
-12 -12
10% 10%
-228%
- Depreciation and Amortization 0.62 0.62
2% 2%
12%
EBIT (Operating Income) EBIT -13 -13
9% 9%
-240%
Net Profit -19 -19
44% 44%
-358%

In millions USD.

Don't miss a Thing! We will send you all news about Plus Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Plus Therapeutics Inc Stock News

Neutral
GlobeNewsWire
7 days ago
HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it received a letter (the “Letter”) from Nasdaq on August 22, 2025, confirming its compliance with Nasdaq Listing Rule 55...
Neutral
GlobeNewsWire
15 days ago
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical com...
Neutral
GlobeNewsWire
18 days ago
HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the “Equity ...
More Plus Therapeutics Inc News

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Head office United States
CEO Marc Hedrick
Employees 21
Founded 1996
Website www.plustherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today